Read by QxMD icon Read


L Iversen, E Dauden, S Segaert, K Freeman, S Magina, D Rigopoulos, D Thaci
BACKGROUND: Although the majority of patients with psoriasis vulgaris are treated exclusively with topical therapies, research to develop more effective topical therapies that are associated with higher patient satisfaction has lagged behind the development of systemic agents. OBJECTIVE: The aim of this literature review was to determine whether there is documented evidence that applying an innovative approach to improving the formulation of active ingredients commonly used in the topical treatment of psoriasis can have a positive effect on clinical outcomes and patient-reported outcomes (PROs)...
April 17, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
Giampiero Girolomoni, Piergiacomo Calzavara Pinton, Antonio Cristaudo, Americo Cicchetti
Psoriasis is a chronic-relapsing skin disorder which requires long-term treatments. Therapeutic options for psoriasis include topical treatments, phototherapy and systemic therapy. However, those treatments, and particularly the topical drug therapies, may present some limitations, including poor efficacy/tolerability ratio and lack of adherence. Recently, the supersaturated aerosol foam formulation of the fixed combination calcipotriene plus betamethasone dipropionate (Cal/BD) has gained major attention because it overcomes some of the limitations associated with other topical treatments...
December 16, 2016: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
Steven R Feldman, Eugenia Levi, Prathamesh Pathak, Sonali Kakatkar, Rajesh Balkrishnan
Treatment of psoriasis is associated with significant healthcare-related costs. A retrospective, observational study was conducted to investigate whether first-line treatment with calcipotriene/betamethasone dipropionate (CBD) fixed-combination topical products would lower the cost impact of psoriasis compared with using the fixed-combination product later in the course of treatment. Patients were classified as being initially treated with CBD combination products (cohort A, n=7307) or other topical psoriasis medications (cohort B, n=9670)...
2016: Skinmed
Tiffany Y Loh, Philip R Cohen
BACKGROUND: Tumor necrosis factor-α (TNF-α) inhibitors, such as infliximab, adalimumab, and certolizumab pegol are effective agents in the treatment of inflammatory bowel disease. Some individuals undergoing anti-TNF-α therapy for Crohn's disease or ulcerative colitis develop psoriasiform lesions. This is a paradoxical finding, as classical psoriasis is known to respond to these agents. PURPOSE: The clinical features of anti-TNF-α-induced psoriatic dermatitis are described...
September 9, 2016: Curēus
Catherine Copley-Merriman, Susan Zelt, Marci Clark, Ari Gnanasakthy
Although some symptoms of dermatologic diseases, such as pruritus and pain, can be subjectively assessed only by patients, the most commonly used endpoints in dermatology drug research traditionally have been clinician-reported outcomes. Research has found that patient-reported outcomes (PROs) were included in only one-quarter of 125 trials conducted between 1994 and 2001. Our objective was to characterize the impact of PROs in dermatology drug development from the patient, prescriber, regulator, payer, and manufacturer perspectives using a case study approach...
April 2017: Patient
Craig Leonardi, Jerry Bagel, Paul Yamauchi, David Pariser, Zhenyi Xu, Anders Moller, Marie Louise Osterdal, Linda Stein Gold
INTRODUCTION: Psoriasis has a major impact on patient quality of life, similar to that seen in other chronic diseases, eg, diabetes. Health-related quality of life (HRQoL) measures are commonly included in clinical trial designs, capturing the disease burden and therapeutic success of a treatment. In the randomized, double-blind, phase III PSO-FAST (<b>Pso</b>riasis vulgaris, a <b>F</b>our-week, vehicle-controlled, efficacy <b>A</b>nd <b>S</b>afety <b>T</b>rial) study (nCT01866163), fixed combination calcipotriene (Cal) 0...
August 1, 2016: Journal of Drugs in Dermatology: JDD
Linda Stein Gold, Mark Lebwohl, Alan Menter, John Villumsen, Monika Rosen, John Koo
BACKGROUND: Calcipotriene 0.005% (Cal)/betamethasone dipropionate 0.064% (BD) aerosol foam was developed as a new treatment option for patients with psoriasis. This pooled analysis evaluated the efficacy of this formulation for 4 weeks of treatment.<BR /> METHODS: Patients aged ≥18 years with mild-severe psoriasis were enrolled into three Phase II/III studies (nCT01536886, nCT01536938, nCT01866163); each study evaluated Cal/BD aerosol foam versus different comparators...
August 1, 2016: Journal of Drugs in Dermatology: JDD
S García-Rodríguez, S Arias-Santiago, G Blasco-Morente, J Orgaz-Molina, A Rosal-Vela, P Navarro, C Magro-Checa, A Martínez-López, J-C Ruiz, E Raya, R Naranjo-Sintes, J Sancho, M Zubiaur
BACKGROUND: MicroRNAs (miRNAs) gene expression regulators are altered in psoriasis suggesting their role in the pathogenesis. OBJECTIVE: To study expression changes of inflammation and toll-like receptor (TLR)-related miRNAs, miRNA-155, let-7i, miRNA-21, miRNA-146a and miRNA-223 in peripheral mononuclear cells (PBMCs) and miRNA-21, miRNA-146a and miRNA-223 in plasma, from chronic plaque-type psoriasis patients who were treatment-naive or had undergone a washout period (n = 11)...
February 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
Laura Korb Ferris, Erine Kupetsky, Neil A M Houston
BACKGROUND: Calcipotriene/betamethasone topical suspension is a topical therapy that is often used as monotherapy as a first-line treatment for plaque psoriasis. The objective of this preliminary, open label, single arm study was to determine the efficacy of adding a topical suspension to a traditional systemic therapy for psoriasis, either methotrexate or acitretin. METHODS: In this exploratory study, eight patients with chronic plaque psoriasis who were on stable methotrexate or acitretin treatment without clearance were treated with once-daily calcipotriene/betamethasone topical suspension...
April 2016: Journal of Clinical and Aesthetic Dermatology
Marianne Lind, Kim Troensegaard Nielsen, Line Hollesen Schefe, Kasper Nørremark, André Huss Eriksson, Hanne Norsgaard, Brian Thoning Pedersen, Karsten Petersson
INTRODUCTION: Previous studies have demonstrated the superior efficacy of a novel aerosol foam formulation of fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064% (BD), compared with the ointment formulation. The aim of this study is to ascertain whether enhanced bioavailability of the active ingredients due to supersaturation and/or occlusive properties can explain the observed greater clinical efficacy. METHODS: Solubility and evaporation experiments were conducted to examine the abilities of Cal/BD aerosol foam ingredients to create a supersaturated environment...
September 2016: Dermatology and Therapy
Mark Lebwohl, Stephen Tyring, Michael Bukhalo, Javier Alonso-Llamazares, Martin Olesen, David Lowson, Paul Yamauchi
OBJECTIVE: To evaluate the efficacy of fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD). DESIGN: Patients were randomized (100:101:101) to receive Cal/BD foam, Cal foam, or BD foam once daily for four weeks. SETTING: Twenty-eight United States centers. PARTICIPANTS: 302 patients (≥18 years) with Psoriasis vulgaris (plaque Psoriasis; ≥mild disease severity by physicians global assessment)...
February 2016: Journal of Clinical and Aesthetic Dermatology
Kevin C Kin, Dane Hill, Steven R Feldman
INTRODUCTION: Psoriasis affects an estimated 2% of the world's population, with higher rates in developed countries. 80% have mild-to-moderate disease and 50 to 80% have scalp involvement. Topical treatments are the mainstay of treatment. AREAS COVERED: Two-compound calcipotriene and betamethasone dipropionate (BD) is a common topical combination therapy consisting of a vitamin D analogue and a corticosteroid. It comes in ointment, gel/suspension, and foam formulations...
June 2016: Expert Review of Clinical Pharmacology
Linda F Stein Gold
Psoriasis is a chronic disease that has a substantial effect on quality of life of patients and often needs long-term treatment. Topical treatments for psoriasis include corticosteroids, vitamin D derivatives, tazarotene, anthralin, tacrolimus, pimecrolimus, and newer formulations of tar. Although many of these treatments are effective, they must be prescribed appropriately and used consistently for a period of weeks to months before clinical evidence of improvement can be seen and patients perceive that the treatment is working...
March 2016: Seminars in Cutaneous Medicine and Surgery
(no author information available yet)
No abstract text is available yet for this article.
April 11, 2016: Medical Letter on Drugs and Therapeutics
Dhwani Mehta, Henry W Lim
Psoriasis is an inflammatory skin condition that affects approximately 2 % of people worldwide. Topical treatments, systemic treatments, biologic agents, and phototherapy are all treatment options for psoriasis. Ultraviolet (UV) B phototherapy is most appropriate for patients with >10 % affected body surface area who have not responded to topical treatments. This review outlines the use, dosage, safety, and efficacy of narrowband UVB (NB-UVB) and targeted phototherapy. NB-UVB and excimer laser are effective treatment options for psoriasis; they are administered two to three times weekly until clearance followed by maintenance treatment before discontinuation...
April 2016: American Journal of Clinical Dermatology
Ralfi Singer, Mehmet Çopur, Ece Nur Yüksel, Emek Kocatürk, Selma Şengiz Erhan
BACKGROUND: Ichthyosis linearis circumflexa is a rare form of ichthyosis characterized by polycyclic and annular lesions which are bordered by a double-edged scale. Netherton syndrome is a genodermatosis in which ichthyosis linearis circumflexa is accompanied by characteristic hair shaft abnormalities and atopic diathesis. Different treatment modalities such as emmolients, keratolytics, calcipotriene, topical corticosteroids, topical calcineurin inhibitors, systemic retinoids, phototherapy and photochemotherapy have been used with variable results...
December 31, 2015: Journal of Dermatological Case Reports
Emel Öztürk Durmaz, Engin Sezer, Sedef Şahin, Işın Doğan Ekici, Ferda Özkan
No abstract text is available yet for this article.
November 2015: Cutis; Cutaneous Medicine for the Practitioner
Craig Leonardi, Jerry Bagel, Paul Yamauchi, David Pariser, Zhenyi Xu, Martin Olesen, Marie Louise Østerdal, Linda Stein Gold
INTRODUCTION: An innovative aerosol foam formulation of calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) designed to improve treatment outcomes. OBJECTIVE: To compare the efficacy and safety of Cal/BD aerosol foam with aerosol foam vehicle in patients with psoriasis. DESIGN: Phase III, double-blind, randomized PSO-FAST (Cal/BD foam in PSOriasis vulgaris, a Four-week, vehicle-controlled, efficacy And Safety Trial) study recruited patients with ≥ mild severity psoriasis of the trunk and/or limbs from 27 US outpatient sites (NCT01866163)...
December 2015: Journal of Drugs in Dermatology: JDD
Gritt Rasmussen, Lene Lillevang Bech, Torben Wager Nielsen
Treatment non-adherence is a complex problem encountered in all therapy areas, particularly in chronic diseases such as psoriasis vulgaris. To address adherence issues, focus is turning towards developing interventions tailored to individual patient needs. Topical therapies remain the mainstay of psoriasis treatment; however, these are associated with additional challenges where preparations may be perceived as messy, inconvenient and time-consuming. Once-daily fixed-combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0...
November 5, 2015: Dermatology and Therapy
John Koo, Stephen Tyring, William P Werschler, Suzanne Bruce, Martin Olesen, John Villumsen, Jerry Bagel
BACKGROUND: An aerosol foam formulation of fixed combination calcipotriene 0.005% (as hydrate; Cal) plus betamethasone dipropionate 0.064% (BD) was developed to improve psoriasis treatment. OBJECTIVES: To compare the efficacy and safety of Cal/BD aerosol foam with Cal/BD ointment after 4 weeks. METHODS: In this Phase II, multicenter, investigator-blind, 4-week trial, adult patients with psoriasis vulgaris were randomized to Cal/BD aerosol foam, Cal/BD ointment, aerosol foam vehicle or ointment vehicle (3:3:1:1)...
2016: Journal of Dermatological Treatment
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"